Exact Sciences Q1 top line up 115%, cologuard revenue up 36%

Exact Sciences (NASDAQ:EXAS) Q1 results:

Revenue: $347.8M (+114.7%); screening: $219.5M (+35.5%); Precision Oncology: $128.4M.

Net loss: ($105.7M); loss/share: ($0.71).

Non-GAAP EBITDA: ($8.2M) (+81.7%).

Quick assets at quarter-end: $1.2B.

EXACT Sciences EPS misses by $0.04, revenue in-line

https://seekingalpha.com/news/3570483-exact-sciences-q1-top-line-up-115-cologuard-revenue-up-36